Repertoire Immune Medicines

4.8 (418) · € 20.99 · En Stock

Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease. Our proprietary DECODE platform is designed to provide a comprehensive understanding of the full repertoire of interactions between T cell receptors and their antigen targets that take place when diseased cells are present. This complex and intricate biological process is known as the immune synapse. We believe the ability to decipher these interactions represents one of the greatest opportunities for innovation in medical science. Repertoire's team operates from sites in Cambridge, Massachusetts and Zurich, Switzerland and uses its DECODE technology to rationally design treatments for cancers, autoimmune disorders and infectious diseases. To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com.

Cara Lowen - Repertoire Immune Medicines

Repertoire Immune Medicines on X: Repertoire's CEO John Cox welcomes new Chief Business Officer John Delyani / X

DECODE - Repertoire Immune Medicines, Inc. Trademark Registration

Repertoire Immune Medicines (@RepertoireIM) / X

Biotech layoffs 2022: Softbank-backed Flagship startup Repertoire Immune Medicines lays off 65, replaces CEO - Boston Business Journal

Repertoire Immune Medicines Company Profile: Financials, Valuation, and Growth

DECODE Platform • Repertoire Immune Medicines

Repertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery & T Cell Receptors • BioTech Health X